Oligomicleotide technologies: Synthesis, production, regulations and applications 29 - 30th November 2000, Hamburg, Germany

Expert Opinion on Biological Therapy

Volumn 1, Issue 2, 2001, Pages 309-317

  Uhlmann, Eugen ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

anticancer; antisense oligonucleotide; aptamer; cellular uptake; Cpg DNA; CPG 7909; G 3139; GEM 231; immunostimulatory activity; locked nucleic acids; spiegelmer; target validation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE;

CHEMISTRY; CLINICAL TRIAL; CONFERENCE PAPER; CPG ISLAND; DRUG DESIGN; ENZYME SPECIFICITY; HUMAN; IMMUNOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CPG ISLANDS; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33745989225     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. CROOKE ST: Vltravene-another piece In the mosaic. Antiscnsc Nucleic Acid Drug Dev. (1998) 8:7-8.
2. UHLMANN E, PEYMAN A: Antisense oligonucleoüdcs: a new therapeutic principle. Cbem. Rev. (1990) 90:543-584.
3. UHLMANN E: Recent advances in the medicinal chemistry of antisense oligonucleotides. Curr. Opln. Drug Discoi'. Dev. (2000) 3:203-213.
4. WANG H, GAI Q, ZENG X, YU D, AGRAWAL S, ZHANG R: Antitumor activity and pharmacokinetics of a mixedbackbone antisense oligonucleotide targeted to the HI a subunit of protein kinase A after oral administration. Proc. Nail. Acad. Sei. USA (1999) 96:13989-13994.
5. UHLMANN E, PEYMAN A, RYTE A, SCHMIDT A, BUDDECKE E: Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol. (1999) 313:268-284.
6. WENGEL J: Synthesis of 3'-C- and 4'-C-branched oligodeoxynucleoUdes and the development of locked nucleic acid (LMA). Ace. Cbem. Res. (1999) 32:301-310.
7. WAHLESTEDT C, SALMI P, GOOD L et al.: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Set. USA. (2000) 97:5633-5638.
8. STETSENKO DA, GAIT MJ: Efficient conjugation of peptides to oligonucleotides by 'native ligation'.J. O;g. Cbem. (2000) 65:4900-4908.
9. COTTER FE, WATERS J, CUNNINGHAM D: Human Bcl-2 antisense therapy for tymphomas. Biochim. Biophys. Acta (1999) 1489: 97-106.
10. KRIEG AM: DNA-based immune enhancers. Ciirr. Opin. DntgDiscov. Dcv. (2000) 3:214-221.
11. AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonuclcotides. Biochim. Biophys. Acta (1999) 1489:53-68.
12. YU D, ZHAO Q, KANDIMALLA ER, AGRAWAL S: Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorgan. Med. Cbem. Lett. (2000) 10:2585-2588.
13. KLUSSMANN S, NOLTE A, BALD R, ERDMANN V, FUERSTE JP: Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. (1996) 14:1112-1115.
14. HOLMLUND JT, MONIA BP, K\VOH TJ, DORR FA: Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development Ciirr. Opin. Mol. Tlicr. (1999) 1:372-385.